Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Short communication

Antiviral activity of ciclesonide acetal derivatives blocking SARS-CoV-2 RNA replication

Genichiro Tsuji \textsuperscript{a},*, 1, Shogo Nakajima \textsuperscript{b, c, d, 1}, Koichi Watashi \textsuperscript{b, c, e}, Shiho Torii \textsuperscript{f, g}, Rigel Suzuki \textsuperscript{h}, Takesuke Fukuhara \textsuperscript{h}, Nobumichi Ohoka \textsuperscript{i}, Takao Inoue \textsuperscript{i}, Yosuke Demizu \textsuperscript{j, **}

\textsuperscript{a} Division of Organic Chemistry, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa, 210-9501, Japan
\textsuperscript{b} National Institute of Infectious Diseases, Research Center for Drug and Vaccine Development, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan
\textsuperscript{c} National Institute of Infectious Diseases, Department of Virology II, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan
\textsuperscript{d} Choju Medical Institute, 19-14 Yamanaka, Noyorishi, Aichi, 441-8124, Japan
\textsuperscript{e} Department of Applied Biological Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, 278-8510, Japan
\textsuperscript{f} Laboratory of Virus Control, Research Institute for Microbial Diseases, Osaka University, Suita, 565-0871, Japan
\textsuperscript{g} Insect-Virus Interactions Unit, Department of Virology, Institute Pasteur, Paris, 75015, France
\textsuperscript{h} Department of Microbiology and Immunology, Graduate School of Medicine, Hokkaido University, N-15, W-7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan
\textsuperscript{i} Division of Molecular Target and Gene Therapy Products, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa, 210-9501, Japan
\textsuperscript{j} Graduate School of Medical Life Science, Yokohama City University, 1-7-29, Yokohama, Kanagawa, 230-0045, Japan

\* Corresponding author. Fax: +81 44 270 6578.
** Corresponding author. Division of Organic Chemistry, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa, 210-9501, Japan. Fax: +81 44 270 6578.
E-mail addresses: gtsuji@nihs.go.jp (G. Tsuji), demizu@nihs.go.jp (Y. Demizu).
Peer review under responsibility of Japanese Pharmacological Society.
1 These authors contributed equally to this study.

Article info

Article history:
Received 3 March 2022
Received in revised form 2 April 2022
Accepted 8 April 2022
Available online 18 April 2022

Keywords:
SARS-CoV2
Antiviral activity
Ciclesonide

Abstract

Ciclesonide (Cic) is approved as an inhalant for asthma and was clinically tested as a candidate therapy for coronavirus disease 2019 (COVID-19). Its active metabolite Cic2 was recently reported to suppress genomic RNA replication of severe acute respiratory syndrome coronavirus 2. In this study, we designed and synthesized a set of ciclesonide-acetal (Cic-acetal) derivatives. Among designated compounds, some Cic-acetal derivatives with a linear alkyl chain exhibited strong viral copy-number reduction activities compared with Cic2. These compounds might serve as lead compounds for developing novel anti-COVID-19 agents.

© 2022 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Coronavirus disease 2019 (COVID-19) has led to an ongoing global public health emergency, resulting in more than 430 million infections and 5.9 million deaths as of February 2022. Vaccines against COVID-19 have been developed and are becoming readily available worldwide. However, there is an urgent need for development of effective therapeutic agents against COVID-19, given the still limited choices for treatment.

Several drugs were explored for clinical use in the treatment of COVID-19 infection, including antiviral agents inhibiting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection/replication and those modulating inflammation to suppress SARS-CoV-2-related pathogenesis. Inhibition of virus propagation by antiviral agents is effective for inhibiting the progression from nonsymptomatic and mild cases to severe disease, thus decreasing the hospital burden and restoring social activities. Various anti-SARS-CoV-2 drugs have been approved for clinical use in some countries, and include remdesivir and molnupiravir, which inhibit viral polymerases; nirmatrelvir, an inhibitor of the main viral protease; and anti-spike antibodies such as casirivimab/imdevimab and sotrovimab. However, as SARS-CoV-2 and related diseases can affect a large population of people globally from diverse backgrounds, new antiviral drugs that widen treatment choices depending on the clinical background remain highly desirable.

https://doi.org/10.1016/j.jphs.2022.04.001
1347-8613/© 2022 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Ciclesonide (Cic) is an inhaled steroid agent for treatment of asthma and is solid under the trade name Alvesco\(^6\). After inhalation, Cic is converted to its active metabolite, desisobutyryl ciclesonide (Cic2) by esterases in the lungs and airways (Fig. 1A).\(^5\) Matsuyama et al. reported that Cic inhibits SARS-CoV-2 replication by targeting SARS-CoV-2 non-structural protein (nsp)-15, which is required for viral replication.\(^5\) However, resistant mutations were mapped to viral nsp3 and nsp4 in their follow-up research, and the precise target of Cic in inhibiting replication of SARS-CoV-2 remains unclear.\(^7\) Our previous study revealed that cyclization, asthma and is solid under the trade name Alvesco\(^6\). After inhalation, Cic is converted to its active metabolite, desisobutyryl ciclesonide (Cic2) by esterases in the lungs and airways (Fig. 1A).\(^5\) Matsuyama et al. reported that Cic inhibits SARS-CoV-2 replication by targeting SARS-CoV-2 non-structural protein (nsp)-15, which is required for viral replication.\(^5\) However, resistant mutations were mapped to viral nsp3 and nsp4 in their follow-up research, and the precise target of Cic in inhibiting replication of SARS-CoV-2 remains unclear.\(^7\) Our previous study revealed that cyclic ciclesonide acetal derivatives possess strong viral copy-number reduction activity and low cytotoxicity compared with Cic2.\(^5\) In the present study, we synthesized the ciclesonide acetal (Cic-acetal) derivatives shown in Fig. 1B for further structure–activity relationship analysis, and evaluated their antiviral activity against SARS-CoV-2 to explore their potential as COVID-19 therapeutics.

We initially synthesized Cic-acetal derivatives from the parent compound, 16α-hydroxyxyprednisolone (Cic-Diol). These compounds could be easily prepared in a single step reaction between Cic-Diol and the corresponding aldehyde (Fig. 1C, Schemes S1 and S2).

Next, anti-SARS-CoV-2 activities of the synthesized compounds were evaluated in a cell culture infection model as reported previously.\(^8\) VeroE6/TMPRSS2 cells were treated with the test compounds during inoculation with a Wuhan strain of SARS-CoV-2 (hCoV-19/Japan/TY-WK-521/2020) at a multiplicity of infection of 0.003 for 1 h, followed by washing off unbound virus and culture with the test compounds for another 24 h before measuring extracellular viral RNA. This result showed that several compounds exhibited concentration-dependent reduction of viral RNA levels (Table 1 and Fig. S1A).

Viral RNA reduction effects were observed in Cic and Cic2; their 50% maximum inhibitory concentrations (IC\(_{50}\), mean ± SD) were 8.6 ± 0.5 μM and 8.5 ± 0.6 μM, respectively, Cic-Diol without an acetel moiety exerted no reduction activity on RNA virus levels. Substitution of a cyclohexyl group on Cic2 to a cyclopentyl or a cyclopropyl group (Cic-cyclo3 and Cic-cyclo5) limited the viral RNA reduction effect. When an aliphatic cyclohexyl group was replaced with an aromatic phenyl group (Cic-Ph), the activity disappeared. However, introduction of a chlorine atom into the phenyl group (Cic-4ClPh, Cic-3ClPh and Cic-2ClPh) restored the activity (IC\(_{50}\) 8.3 ± 1.2, 8.5 ± 1.2, and 9.1 ± 0.2 μM, respectively). Among designated compounds Cic-C3, Cic-C6, Cic-C9, and Cic-C12, reduction of viral RNA increased concomitantly with increasing alkyl chain length. The IC\(_{50}\) were >30, 5.7 ± 2.5, 6.9 ± 1.3, and 6.1 ± 2.7 μM, respectively. Conversely, viral RNA reduction effect was decreased in the derivative with alkyl chain length of 15 (Cic-C15), indicating that there is an appropriate length of alkyl side chain for optimal viral RNA reduction effect (IC\(_{50}\) 20.8 ± 3.8 μM). These compounds showed no cytotoxicity, except for Cic-C9 at high concentrations (50% maximum cytotoxic concentration [CC\(_{50}\), mean ± SD] 21.8 ± 0.9 μM) (Table 1 and Fig. S1B). The results using a human-derived lung epithelial cell line, Calu-3 cells, also showed that the effect in viral RNA reduction of Cic-C6, Cic-C9 and Cic-C12 were comparable with those of Cic (Table 1 and Fig. S1C) without cytotoxicity (Table 1 and Fig. S1D). The IC\(_{50}\) of Cic, Cic-C6, Cic-C9, and Cic-C12 in this assay were 4.5 ± 3.9, 10.9 ± 13.6, 8.9 ± 7.2, and 16.1 ± 9.2 μM, respectively. In Calu-3 cells, Cic showed the highest IC\(_{50}\) value.

![Fig. 1. Chemical structures of ciclesonide derivatives. Ciclesonide (Cic), an active metabolite of Cic, desisobutyryl ciclesonide (Cic2) and the parent compound, Cic-Diol (A). Ciclesonide acetal (Cic-acetal) derivatives (B). The representative synthetic scheme of Cic-acetal derivatives (C).](image-url)
(4.5 ± 3.9 μM) among the tested compounds. However, the activity of Cic2 was apparently decreased (IC₅₀ 13.4 ± 10.0 μM). Because it has been reported that Cic exhibits similar antiviral inhibitory activity in both VeroE6/TMPRSS and Calu-3 cells, this result might be due to the difference in membrane permeability of Cic2 in the respective cells.

These results suggest that the hydrophobicity of the synthesized compounds might contribute to antiviral activities, i.e., the hydrophobicity of the acetal moiety may affect the cell membrane permeability. To assess this assumption, the hydrophobicity of the compounds was estimated by the retention time in reversed-phase HPLC analysis. The results indicated a correlation between their hydrophobicity and antiviral activity (Table S1). For instance, no activity was observed for Cic-PEG2Me with the hydrophilic ethylene glycol (Fig. S1A). Furthermore, activities comparable with Cic-C9 were observed in Cic-C9-OAc, Cic-C9-NHAc, and Cic-C9-N₃, which have the same C9 chain length as Cic-C9 but different functional groups at the terminal, indicating similar hydrophobicity (Fig. S1A). In contrast, when the hydrophobicity of the acetal moiety became too high (Cic-C12—Cic-C15), the antiviral activity tended to be weakened (Cic-C15 in Fig. S1A and Cic-C12 in Fig. S1C).

Next, we tested whether these compounds were also effective against SARS-CoV-2 variants (Delta [Table 2 and Fig. S2A], Omicron [Table 2 and Fig. S2B], a variant carrying an E406W mutation that is resistant to the casirivimab/imdevimab antibody cocktail [Table 2 and Fig. S2C], and an R10/E796G C799F variant resistant to remdesivir [Table 2 and Fig. S2D]) in reducing viral RNA replication. Delta, Omicron, and E406W possess mutations in the receptor binding domain of the spike protein, and R10/E796G C799F carries a mutation in the polymerase region. Our compounds showed antiviral effects on these variants comparable with those seen against the Wuhan strain (Table 1 and Fig. S1A). Of note, Cic-C6, Cic-C9 and Cic-C12 were found to be effective against a mutant in which viral RNA reduction effect was attenuated in Cic and Cic2 (Fig. S2D).

In summary, we synthesized Cic-acetal derivatives and demonstrated their antiviral activity against SARS-CoV-2 variants. Among the synthesized derivatives, compounds with linear alkyl side chains on the acetal moiety, Cic-C6 and Cic-C9, exhibited strong reduction in viral RNA levels. The parent compound, Cic2, is a single optically active compound, however, Cic-acetal derivatives synthesized in this study are diastereomeric mixtures because of newly-constructed acetal moiety. Additional studies might clarify the relationship between the stereochemistry of the Cic-acetal derivatives and their antiviral activities. These types of compounds were also effective against mutant strains of SARS-CoV-2 causing COVID-19 infectious disease. In particular, these compounds were found to be more effective against variants for which Cic or its active metabolite Cic2 were less effective. Further studies are required to reveal the target molecules of Cic in the inhibition of viral replication of SARS-CoV-2, leading the rational design of Cic-based COVID-19 therapeutics.

**Funding sources**

This work was supported by a Grant-in-Aid for Scientific Research (KAKENHI, 19K16333 to G.T.) by the Japan Society for the
Promotion of Science, and by the Agency for Medical Research and Development (AMED) (Grant No. JP20fk0108411).

Declaration of competing interest

The authors indicated no potential conflicts of interest.

Acknowledgements

VeroE6/TMPRSS2 cells were kindly provided by Dr. Makoto Takeda at Department of Virology III, National Institute of Infectious Diseases. We also thank the isolation of the SARS-CoV-2 clinical strains by Department of Virology I, Department of Veterinary Science, Center for Influenza and Respiratory Virus Research, and Department of Pathology at National Institute of Infectious Diseases. We thank Gillian Campbell, PhD, from Edanz (https://www.jp.edanz.com/ac) for editing a draft of this manuscript.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jphs.2022.04.001.

References

1. WHO coronavirus (COVID-19) dashboard. Available online: https://covid19.who.int/ (cited 28 February, 2022.)
2. NIH COVID-19 treatment guidelines; antiviral therapy. Available online: https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ (cited 21 February, 2022.)
3. NIH COVID-19 treatment guidelines; clinical management summary. Available online: https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/clinical-management-summary/ (cited 21 February, 2022.)
4. WHO Therapeutics and COVID-19: living guideline. Available online: https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.1 (cited 21 February, 2022.)
5. Nave R, Watz H, Hoffmann H, Boss H, Magnussen H. Deposition and metabolism of inhaled ciclesonide in the human lung. Eur Respir J. 2010;36:1113–1119. https://doi.org/10.1183/09031936.00172309.
6. Matsuyama S, Kawase M, Nao N, et al. Molecular pharmacology of ciclesonide against SARS-CoV-2. J Allergy Clin Immunol. 2020;146:330–331. https://doi.org/10.1016/j.jaci.2020.05.029.
7. Matsuyama S, Kawasea M, Nao N, et al. The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting the viral replication-transcription complex in cultured cells. J Virol. 2021;95:e01648. https://doi.org/10.1128/JVI.01648-20, 20.
8. Tsuji G, Yonemitsu K, Ito T, et al. Development of ciclesonide analogues that block SARS-CoV-2 RNA replication. Bioorg Med Chem Lett. 2021;43:128052. https://doi.org/10.1016/j.bmcl.2021.128052.
9. Ohashi H, Watashi K, Saso W, et al. Potential anti-COVID-19 agents, cepharanthine and nel斐navir, and their usage for combination treatment. iScience. 2021;24:102367. https://doi.org/10.1016/j.isci.2021.102367.
10. Torii S, Kim KS, Koseki J, et al. Characterization of various remdesivir-resistant mutations of SARS-CoV-2 by mathematical modeling and molecular dynamics simulation. bioRxiv. 2022. https://doi.org/10.1101/2022.02.22.481436.